Leticia Szadai | Medicine and Dentistry | Best Researcher Award

Published on by Invention Awards

Best Researcher Award

Leticia Szadai
Lund University, Sweden

Leticia Szadai
Affiliation Lund University
Country Sweden
Google Scholar ID CNcrXOIAAAAJ
Documents 27
Citations 175
h-index 7
Subject Area Medicine and Dentistry
Event International Invention Awards

The Best Researcher Award recognizes researchers whose scholarly activities have contributed to the advancement of knowledge and innovation within their respective disciplines. Leticia Szadai of Lund University has developed a research profile centered on melanoma biology, proteomics, biomarker discovery, and translational cancer research. Her work integrates advanced molecular analysis with clinical applications, supporting improved understanding of melanoma progression, recurrence mechanisms, and therapeutic opportunities. Through collaborative research efforts, she has contributed to the generation of valuable datasets and analytical frameworks relevant to modern oncology research.[1]

Abstract

This article summarizes the academic achievements and research contributions of Leticia Szadai. Her work primarily focuses on melanoma proteomics, molecular pathology, biomarker identification, and translational oncology. Through participation in multidisciplinary investigations, she has contributed to the development of proteomic resources and analytical methods that support precision medicine approaches in cancer research.[2]

Keywords

Melanoma, Proteomics, Molecular Pathology, Biomarkers, Translational Medicine, Cancer Research, Precision Oncology, Tumor Biology.

Introduction

Advances in cancer research increasingly depend on interdisciplinary methodologies that connect molecular science with clinical practice. Leticia Szadai has contributed to this field through studies examining melanoma biology and the molecular factors associated with disease progression and recurrence. Her research reflects contemporary efforts to improve diagnostic and prognostic strategies through large-scale proteomic investigation.[3]

Research Profile

As a researcher affiliated with Lund University, Leticia Szadai has participated in projects involving molecular oncology, clinical proteomics, and translational medicine. Her publication record demonstrates engagement with collaborative international research initiatives focused on melanoma tissue analysis, mitochondrial regulation, immune response mechanisms, and biomarker discovery. These efforts contribute to the broader objective of enhancing evidence-based cancer management.[4]

Research Contributions

  • Contributed to studies establishing comprehensive melanoma proteome atlases.
  • Investigated molecular pathology and protein expression patterns in melanoma.
  • Explored mitochondrial dysfunction and immune response dysregulation associated with melanoma recurrence.
  • Participated in biomarker discovery using archived tumor samples and advanced proteomic technologies.
  • Supported research into kinase signaling pathways and translational applications in oncology.

Publications

  • The Human Melanoma Proteome Atlas—Complementing the Melanoma Transcriptome (2021).
  • The Human Melanoma Proteome Atlas—Defining the Molecular Pathology (2021).
  • Mitochondrial and Immune Response Dysregulation in Melanoma Recurrence (2023).
  • Deep Proteomic Analysis on Biobanked Paraffin-Archived Melanoma with Prognostic/Predictive Biomarker Read-Out (2021).
  • A Biobanking Turning-Point in the Use of Formalin-Fixed, Paraffin Tumor Blocks to Unveil Kinase Signaling in Melanoma (2021).

Research Impact

The available citation metrics indicate that Leticia Szadai’s research outputs have attracted scholarly attention within oncology and translational medicine communities. Her involvement in high-impact collaborative studies has supported the development of proteomic resources that facilitate future investigations into melanoma progression, biomarker validation, and personalized therapeutic strategies. These contributions demonstrate measurable academic influence and continuing relevance to cancer research.[5]

Award Suitability

Leticia Szadai’s research portfolio aligns with the objectives of the International Invention Awards and the Best Researcher Award category. Her scholarly contributions reflect innovation in proteomic methodology, translational cancer research, and biomarker development. The combination of publication activity, collaborative leadership, and clinically relevant outcomes supports recognition for contributions to medicine and dentistry-related scientific advancement.[6]

Conclusion

Leticia Szadai has established a research profile characterized by rigorous investigation of melanoma biology and proteomics. Her contributions to translational oncology, biomarker discovery, and molecular pathology have supported scientific understanding of cancer mechanisms and potential clinical applications. These achievements provide a strong foundation for academic recognition through the Best Researcher Award.

References

  1. Elsevier. (n.d.). Google Scholar author details: Leticia Szadai
    https://scholar.google.com/citations?hl=hu&user=CNcrXOIAAAAJ
  2. Betancourt LH et al. (2021). The Human Melanoma Proteome Atlas—Complementing the Melanoma Transcriptome. Clinical and Translational Medicine.
    https://doi.org/10.1002/ctm2.451
  3. Betancourt LH et al. (2021). The Human Melanoma Proteome Atlas—Defining the Molecular Pathology. Clinical and Translational Medicine.
    https://doi.org/10.1002/ctm2.473
  4. Szadai L et al. (2023). Mitochondrial and Immune Response Dysregulation in Melanoma Recurrence. Clinical and Translational Medicine.
    https://doi.org/10.1002/ctm2.1495
  5. Szadai L et al. (2021). Deep Proteomic Analysis on Biobanked Paraffin-Archived Melanoma with Prognostic/Predictive Biomarker Read-Out. Cancers.
    https://doi.org/10.3390/cancers13236105
  6. Velasquez E et al. (2021). A Biobanking Turning-Point in the Use of Formalin-Fixed, Paraffin Tumor Blocks to Unveil Kinase Signaling in Melanoma. Clinical and Translational Medicine.
    https://doi.org/10.1002/ctm2.466

A. Marcell Szasz | Medicine and Dentistry | Excellence in Research Award

Published on by Invention Awards

Excellence in Research Award

A. Marcell Szasz
Semmelweis University, Hungary

A. Marcell Szasz
Affiliation Semmelweis University
Country Hungary
Scopus ID 24723204500
Documents 147
Citations 4,107
h-index 29
Subject Area Medicine and Dentistry
Event International Invention Awards
Google Scholar ID eeJzLNQAAAAJ

The Excellence in Research Award recognizes researchers whose scholarly activities demonstrate sustained contributions to scientific advancement, interdisciplinary collaboration, and measurable research impact. A. Marcell Szasz of Semmelweis University has developed a notable academic profile in medicine and cancer research through influential publications, biomarker studies, translational oncology investigations, and evidence-based clinical analyses.[1] His publication record and citation performance indicate significant engagement within the international scientific community.[2]

Abstract

A. Marcell Szasz has contributed to the fields of oncology, molecular medicine, prognostic biomarker analysis, and cancer outcome prediction. His research portfolio encompasses gene-expression studies, clinical meta-analyses, cancer progression modeling, and translational medical investigations. Through collaborations with international research teams, his work has informed understanding of disease mechanisms and patient stratification approaches in modern oncology.[2]

Keywords

Oncology, Biomarkers, Precision Medicine, Cancer Research, Meta-analysis, Gene Expression, Translational Medicine, Clinical Research.

Introduction

Research excellence is frequently evaluated through scientific influence, publication quality, citation impact, and contribution to knowledge development. Within this context, A. Marcell Szasz has established a scholarly presence through studies addressing cancer biology, prognostic biomarkers, and therapeutic outcomes. His work contributes to evidence-based approaches used in clinical and translational medicine.[3]

Research Profile

The researcher maintains a substantial publication portfolio consisting of 147 indexed documents, more than 4,100 citations, and an h-index of 29. His academic activity is primarily associated with medicine, oncology, pathology, molecular diagnostics, and clinical outcome assessment. These metrics reflect both productivity and sustained visibility within international scientific literature.[1]

Research Contributions

  • Investigation of microRNA regulation and metastatic progression in breast cancer.
  • Development and validation of transcriptomic biomarkers associated with survival outcomes.
  • Comprehensive meta-analyses supporting clinical decision-making in oncology.
  • Studies examining genomic alterations and evolutionary pathways of metastatic disease.

Publications

Among his most cited publications are studies on miR-31 and breast cancer metastasis, transcriptomic biomarker validation in gastric cancer, urachal carcinoma meta-analysis, tamoxifen-response biomarkers, and phylogenetic analyses of metastatic progression.[4] These works have received substantial scholarly attention and have been referenced extensively in subsequent research.

Research Impact

The citation performance associated with A. Marcell Szasz demonstrates broad engagement from researchers across oncology, pathology, molecular biology, and clinical medicine. His publications have contributed to methodological refinement, biomarker validation, and evidence synthesis efforts that support future investigations and clinical translation.[5]

Award Suitability

The Excellence in Research Award emphasizes scientific rigor, research influence, and sustained scholarly contribution. Based on publication metrics, citation impact, interdisciplinary collaborations, and documented contributions to cancer research, A. Marcell Szasz demonstrates characteristics commonly associated with distinguished academic achievement and research leadership.[6]

Conclusion

A. Marcell Szasz has contributed meaningfully to contemporary oncology research through studies addressing biomarkers, disease progression, and clinical outcomes. His publication record, citation profile, and participation in influential collaborative projects provide a strong foundation for recognition within an academic award framework focused on research excellence.

References

  1. Elsevier. (n.d.). Scopus author details: A. Marcell Szasz, Author ID 24723204500. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=24723204500
  2. Valastyan S., Reinhardt F., et al. (2009). miR-31 inhibits breast cancer metastasis. Cell.
    DOI: https://doi.org/10.1016/j.cell.2009.03.047
  3. Szász A.M., Lánczky A., et al. (2016). Cross-validation of survival associated biomarkers in gastric cancer. Oncotarget.
    DOI: https://doi.org/10.18632/oncotarget.10337
  4. Brown D., Smeets D., Székely B., Szasz A.M., et al. (2017). Phylogenetic analysis of metastatic progression in breast cancer. Nature Communications.
    DOI: https://doi.org/10.1038/ncomms14944
  5. Mihály Z., Kormos M., Lánczky A., et al. (2013). Gene expression-based biomarkers predicting outcome after tamoxifen treatment.
    DOI: https://doi.org/10.1007/s10549-013-2619-y
  6. Szarvas T., Módos O., Niedworok C., et al. (2016). Clinical, prognostic, and therapeutic aspects of urachal carcinoma.
    DOI: https://doi.org/10.1016/j.urolonc.2016.04.012

John Dundon | Medicine and Dentistry | Research Excellence Award

Published on by Invention Awards

Dr. John Dundon | Medicine and Dentistry | Research Excellence Award 

Orthopedic Research Institute of New Jersey | United States

Dr. John M. Dundon is a board-certified orthopedic surgeon and clinician–scientist with a distinguished research profile focused on adult reconstruction, total hip and knee arthroplasty, surgical innovation, and value-based orthopedic care. As a Full Partner at Tri-County Orthopedics and previously at the Orthopedic Institute of New Jersey, Dr. Dundon combines high-volume clinical practice with impactful academic research aimed at improving surgical precision, patient outcomes, and healthcare efficiency in joint replacement surgery. A central theme of Dr. Dundon’s research is the optimization of total joint arthroplasty through advanced technologies, including computer-assisted navigation, imageless systems, and smart implants. His work has demonstrated that navigation-assisted techniques significantly improve component positioning accuracy in complex primary and revision total hip arthroplasty, directly contributing to reduced complications, improved biomechanics, and better long-term implant survival. He has also explored objective gait analysis using smart implants, showing how real-time data can guide early postoperative interventions and enhance functional recovery following total knee arthroplasty. Dr. Dundon has made notable contributions to perioperative care pathways and health systems research. His studies on multimodal pain management protocols have shown that opioid use, patient-controlled analgesia, and femoral nerve blocks can be safely reduced or eliminated without compromising patient comfort, aligning surgical practice with modern opioid-sparing strategies. Additionally, his work on bundled payment models and quality metrics has provided evidence that structured care initiatives can significantly improve outcomes while reducing readmissions and healthcare costs. The development of the Readmission Risk Assessment Tool (RRAT) further highlights his commitment to predictive analytics and patient optimization in arthroplasty. His research portfolio also addresses implant biomechanics, tribocorrosion, femoral stem sizing, leg-length discrepancy correction, and postoperative imaging utilization, reflecting a comprehensive approach to both technical and clinical challenges in orthopedic surgery. Dr. Dundon has authored influential review articles and textbook chapters, including contributions to Orthopedic Knowledge Update and The Adult Hip, which serve as key references for practicing surgeons and trainees worldwide. With an extensive record of peer-reviewed publications, national and international presentations, and leadership roles within major orthopedic societies such as the American Academy of Orthopaedic Surgeons and the American Association of Hip and Knee Surgeons, Dr. Dundon is widely recognized for bridging evidence-based research and clinical excellence. His research profile reflects sustained innovation, interdisciplinary collaboration, and a clear commitment to advancing the safety, effectiveness, and value of modern joint replacement surgery.

Citation Metrics (Scopus)

1000
600
400
200
50
0

Citations
641

i10index
20

h-index
9

Citations

i10-index

h-index

View Scopus Profile

Featured Publications

Carlos Escobar | Medicine and Dentistry | Best Researcher Award

Published on by Invention Awards

Prof. Dr. Carlos Escobar | Medicine and Dentistry | Best Researcher Award

Prof. Dr. Carlos Escobar | Hospital La Paz, Madrid | Spain

Dr. Carlos Escobar Cervantes is a leading cardiologist and researcher based in Madrid, Spain. With over two decades of experience in cardiovascular medicine, he has held esteemed roles in top Spanish hospitals, contributed prolifically to scientific literature, and has played leadership roles within major cardiology societies. He currently serves as Facultativo Adjunto del Servicio de Cardiología at Hospital Universitario La Paz and is the Scientific Director of the Consorcio DTX, focusing on digital therapeutics (DTx) and AI in health. His work bridges clinical expertise and digital innovation, making him a pioneer in the integration of artificial intelligence in cardiovascular care. Dr. Escobar’s dedication extends beyond patient care—he is also a respected academic and educator, shaping future medical professionals. His contribution to cardiovascular pharmacology, hypertension, ischemic heart disease, and public health through clinical trials, publications, and professional society work makes him an exemplary candidate for international recognition.

Profile

Orcid

Education

Dr. Carlos Escobar Cervantes earned his Medical Degree in Medicine and Surgery from the Universidad Autónoma de Madrid (1993–1999). He pursued academic excellence and scientific inquiry further by completing a PhD in Medicine at the Universidad de Alcalá in 2007, where he was awarded the prestigious distinction of Sobresaliente Cum Laude, by unanimous decision of the examining board. This rigorous academic path provided him with a strong foundation for his career in internal medicine, clinical cardiology, and scientific research. Additionally, his commitment to academic growth is reflected in his successful qualification as a Profesor Ayudante Doctor recognized by ANECA in June 2011. Further enriching his academic and leadership portfolio, Dr. Escobar completed the Leadership Development Program in Public Healthcare Organizations from ESADE Business School (2011–2012), one of Spain’s most prestigious business institutions. His education uniquely combines clinical, scientific, and managerial expertise—vital for innovative cardiovascular leadership.

Professional Experience

Dr. Escobar Cervantes has held successive and prestigious roles in cardiology across some of Madrid’s foremost healthcare institutions. He began his career as a Médico Adjunto de Cardiología at Hospital Universitario Ramón y Cajal (2006–2008), then transitioned to Hospital Universitario Infanta Sofía (2008–2012), and has been serving at Hospital Universitario La Paz since 2012. Currently, he also coordinates outpatient cardiology services and care continuity at La Paz, a role he took on in June 2023, showcasing his capacity for healthcare system organization and innovation. Since December 2023, Dr. Escobar has been the Scientific Director of the Consorcio DTX, focused on the application of digital health tools, including AI, in cardiology. He is also the Co-founder of Samira DTX, emphasizing his proactive stance in developing evidence-based digital therapeutic solutions. His career represents a seamless integration of bedside excellence, scientific leadership, and organizational impact in Spanish and international cardiology.

Research Interests

Dr. Escobar’s research focuses on ischemic heart disease, arterial hypertension, atrial fibrillation, and pulmonary thromboembolism. As both principal investigator and co-investigator, he has played key roles in clinical trials exploring innovative therapies in these domains. In recent years, he has expanded his research to encompass digital therapeutics (DTx) and the application of artificial intelligence (AI) in cardiovascular medicine. He is an active contributor to the Sociedad Española de Cardiología (SEC) and the European Society of Cardiology, where he is a member of the cardiovascular pharmacology and hypertension working groups. His research is deeply translational—bringing bench-side developments to bedside application. His commitment to improving cardiovascular care outcomes through technological innovation, patient-centered care models, and robust clinical investigation underscores his status as a forward-thinking leader in cardiovascular science. Dr. Escobar’s dual commitment to both scientific discovery and clinical impact has made him a valued voice in the cardiology research community.

Awards and Professional Recognition

Dr. Carlos Escobar is a highly respected figure in cardiology, having served as President of the Clinical Cardiology Section of the Sociedad Española de Cardiología (SEC). He has been a member of the SEC’s Research Agency and is an active contributor to several working groups under both SEC and the European Society of Cardiology (ESC). His academic and research contributions have earned him memberships in international editorial boards such as the World Journal of Hypertension, ISRN Nephrology, and the Journal of Cardiology and Therapeutics. His peer-review activity includes esteemed journals like Annals of Internal Medicine, Diabetes Care, and the Journal of Hypertension, reflecting his reputation as an authority in cardiovascular science. These honors reflect a career distinguished not only by scientific productivity but also by community trust and professional excellence. His leadership, publications, and collaborative spirit make him a worthy nominee for high-level international awards.

Publications Top Notes

Cost-utility analysis of dapagliflozin for the treatment of symptomatic chronic heart failure in Spain

The gut microbiota and its role in the development of cardiovascular disease

Management of children with heterozygous familial hypercholesterolaemia worldwide: a meta-analysis

Artificial intelligence: a promising tool for the clinical cardiologist

Magnitude of chronic kidney disease in Spain

Conclusion

Dr. Carlos Escobar Cervantes exemplifies the union of clinical excellence, academic integrity, and technological foresight. His contributions to cardiology span groundbreaking clinical research, digital health innovation, and transformative educational leadership. His work has directly improved cardiovascular care standards in Spain and beyond, earning him recognition across editorial boards, societies, and digital medicine consortia. Dr. Escobar is not only a scientific leader but also an innovator, teacher, and strategist, positioning him as a well-rounded and future-focused candidate for any top-tier international medical or scientific award. His pioneering initiatives in AI-driven cardiovascular therapeutics, combined with his extensive academic publications and clinical leadership, embody the spirit of 21st-century medical excellence. He is therefore highly recommended for recognition in awards celebrating innovation, excellence, and translational impact in cardiovascular medicine.